Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022

Motoko Yanagita(Kyoto University), Naoki Kashihara(Kawasaki Medical School), Kent Doi(University of Tokyo Hospital), Takehito Yamamoto(University of Tokyo Hospital), Emiko Sakaida(Chiba University Hospital), Kazuhiro Yamamoto(Okayama University), Takeshi Matsubara(Shimane University), Yuichi Koizumi(Fuchu Hospital), Masaomi Nangaku(The University of Tokyo), Kimikazu Yakushijin(Kobe University Hospital), Yusuke Kobayashi(University of Tsukuba), Satoru Muto(Juntendo University), Yukio Ando(Nagoya University Hospital), Mototsugu Oya(Keio University), Takahiro Hatta(Anjo Kosei Hospital), Hirokazu Okada(University of Tsukuba), Nao Takano(Nagoya University), Takamitsu Inoue(International University of Health and Welfare), Yuta Okumura(National Hospital Organization Kyushu Cancer Center), Yutaka Fujiwara(Aichi Cancer Center), Hideki Shimodaira(Tohoku Medical and Pharmaceutical University), Hiroyuki Nishiyama(University of Tsukuba), Koji Matsumoto(Showa University), Yusuke Okuda(Kitasato University), Chihiro Kondoh(Toranomon Hospital), Taigo Kato(Osaka City University), Satoko Ichioka(Shiga University of Medical Science), Yugo Shibagaki(FIND), Kenji Ishikura(Kitasato University), Norio Hanafusa(Nihon University), Junichi Hoshino(Japanese Society for Dialysis Therapy), Hiroshi Kitamura(University of Toyama), Akiko Uchida(Seirei Social Welfare Community), Sumío Hirata(Ashiya University), Kazuo Matsubara(Wakayama Medical University), Yoshinari Yasuda(Nagoya University)

Clinical and Experimental Nephrology

October 25, 2023

Cited by 13

Related Papers

|Intensive Care Medicine|2021|5.1k

|Critical Care Medicine|2021|2.8k

|The Lancet|2017|923

|Nature|2021|603

|Kidney International|2020|548